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1. Introduction 
Oral squamous cell carcinoma cells in the gingiva frequently invade the maxillary or 
mandibular bone. The clinical consequences of oral squamous cell carcinoma-induced bone 
destruction include a worse prognosis, a high morbidity rate, hypercalcemia, and nerve 
paralysis (Brown, et al., 2002; Hicks, et al., 1997; Shaw, et al., 2004). Patients with oral 
squamous cell carcinoma and associated bone invasion require bone resection, which has a 
major influence on their functional outcome. However, the mechanism of bone destruction 
by oral squamous cell carcinoma remains unresolved.  
Localization of tumor cells within the bone leads to the production of tumor-associated 
factors synthesized either directly by the tumor cell itself or as a result of tumor/stromal 
interactions. These tumor-associated factors converge on the pre-osteoblast or stromal cell to 
cause an increase in the level of receptor activator of nuclear factor kappa  ligand (RANKL) 
and/or a decrease in that of osteoprotegerin (OPG), which ultimately results in the 
activation and survival of osteoclasts, with osteolytic lesions being the result (Roodman GD 
& Dougall WC, 2008). Bone destruction then leads to the release of growth factors derived 
from bone, including transforming growth factor- (TGF-), insulin-like growth factors 
(IGFs), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and bone 
morphogenetic proteins (BMPs; (Kayamori, et al., 2010; Roodman GD, 2004; Roodman GD & 
Dougall WC, 2008; Shibahara, et al., 2005). These factors increase the production of tumor-
associated factors or promote tumor growth directly. Thus, tumor cell proliferation and 
production of tumor-associated factors through the signaling of these pathways are 
promoted, and the vicious cycle continues. 
Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family (Takigawa 
M, et al., 2003), which consists of 6 members: CCN1 (Cyr61), CCN2 (CTGF), CCN3 (NOV), 
CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3; (Katsube K, et al., 2009; Kubota S & 
Takigawa M, 2007b; Perbal B, 2004), all of which possess an NH2-terminal signal peptide 
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indicative of their secreted-protein nature. CCN proteins share a common molecular 
structure consisting of an insulin-like growth factor (IGF)-binding protein-like module 
(IGFBP), von Willebrand factor type C repeat (VWC), thrombospondin type-1 repeat (TSP1), 
and C-terminal module (CT), except in the case of CCN5, which lacks the CT module. The 
N-terminal and C-terminal halves of the proteins are connected by a hinge region that is not 
conserved and is particularly sensitive to proteolysis (Dean, et al., 2007; Kireeva, et al., 1996). 
By means of these modules, the CCN2 protein interacts with a number of extracellular 
molecules. The IGFBP motif is responsible for binding IGF (Bork P, 1993), albeit studies with 
CCN2 have demonstrated that the interaction of CCN2 with IGF occurs with a much lower 
affinity than that of authentic IGFBPs (Yang DH, et al., 1998 Jul;). The VWC motif binds to 
integrin v3 (Perbal B & Takigawa M, 2005) and has been implicated as a binding site for 
BMP-4 and TGF- family members, this binding modulating their activity (Abreu JG, et al., 
2002). The TSP-1 motif is involved in binding to integrin 61, v3 (Perbal B & Takigawa M, 
2005), LRP1 and LRP6 (Gao & Brigstock, 2003; Segarini PR, et al., 2001), and VEGF (Inoki I, et 
al., 2002). Finally, the CT motif binds integrin v3 and cell-surface heparan sulfate 
proteoglycans (HSPGs; (Gao R & Brigstock DR, 2004). These different domains of CCN2 could 
be responsible for the differential signaling resulting in its various biological activities (Fig. 1).  
 
Fig. 1. CCN2-interacting proteins and receptors of CCN2. CCN2 protein interacts with a 
variety of cell-surface signal-transducing receptors and extracellular ligands, including 
various integrins, heparan sulfate proteoglycans (HSPG), and LRPs. Receptors and 
extracellular proteins that interact with 3 of the 4 conserved CCN2 domains are shown. 
One of the most prominent functions of CCN2 is its role in cell adhesion. When immobilized 
on solid surfaces in cell cultures, CCN2 proteins can support the adhesion of most adherent-
cell types through integrins and HSPGs and induce adhesive signaling. Adhesion of CCN2 to 
human skin fibroblasts occurs through ┙6┚1-HSPGs and rapidly induces the formation of ┙ 
6┚1-containing focal adhesion complexes, activation of focal adhesion kinase (FAK), paxillin, 
and Rac, as well as reorganization of the actin cytoskeleton and formation of filopodia and 
lamellipodia (C. C. Chen, et al., 2001). CCN2 can serve as an adaptor for other extracellular 
matrix proteins to promote cell adhesion, as exemplified by the binding of CCN2 to fibronectin 
and perlecan (Y. Chen, et al., 2004; Nishida, et al., 2003). In addition to supporting cell 
adhesion, one of the ubiquitous activities of CCN proteins is the regulation of cell migration. 
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CCN2 proteins stimulate the migration of many mesenchymal cell types (Babic, et al., 1999; 
Grzeszkiewicz, et al., 2001; Lin, et al., 2003; Shimo T, et al., 1998; Shimo T, et al., 1999).  
CCN2 was originally discovered in, and purified from, the conditioned medium of cultured 
vein endothelial cells (Bradham, et al., 1991). In 1998, Shimo et al. reported that knockdown 
of ccn2 expression results in the suppression of the proliferation and migration of normal 
vascular endothelial cells (Shimo T, et al., 1998). Subsequently, CCN2 was shown to induce 
angiogenesis in corneal implants (Babic, et al., 1999) and chick chorioallatonic membranes 
(Shimo T, et al., 1999). CCN2 also induces chemotaxis (inducing directional cell migration) 
and chemokinesis (random cell movement) in endothelial cells (Babic, et al., 1999; Babic, et 
al., 1998; Lin, et al., 2003; Shimo T, et al., 1999). Through direct binding to integrin ┙v┚3, 
CCN2 can recapitulate angiogenic events in vitro by promoting endothelial cell adhesion, 
migration, proliferation, and tubule formation (Babic, et al., 1999; Leu, et al., 2002; Lin, et al., 
2003; Shimo T, et al., 1999). 
CCN2 knockout mice die just after birth due to respiratory failure (Ivkovic S, et al., 2003). 
This failure is attributed to hypoplasia of the thoracic skeleton and deformity of the oral 
cavity (palatal cleft and shortened mandible). CCN2 knockout mice also show skeletal 
dysmorphisms as a result of impaired chondrocyte proliferation and reduced extracellular 
matrix with altered composition within the hypertrophic chondrocytic zone in the growth 
plate. Histologically, angiogenesis and formation of tartrate-resistant acid phosphatase 
(TRAP)-positive osteoclast-like cells, as well as critical protease expression in the growth 
plate, are impaired and accompanied by defective replacement of cartilage by bone during 
endochondral ossification (Nakanishi T, et al., 2000; Nishida T, et al., 2000; Shimo T, et al., 
2005). These results demonstrate that CCN2 is important for cell proliferation and matrix 
remodeling during chondrogenesis, and is a key regulator coupling extracellular matrix 
remodeling to angiogenesis at the growth plate. The biological activities of CCN2 also 
include the development of Meckel’s cartilage (Shimo T, et al., 2004) and tooth germs 
(Shimo T, et al., 2002).  
Next we will summarize research indicating the essential roles of CCN2 and related 
molecules in the bone destruction caused by cancer. 
2. Cancers and CCN2 
CCN2 proteins carry out their biological activity through binding and cell surface integrins 
(Lau LF & Lam SC, 1999), and elevated CCN2 expression has been observed in breast 
cancers (Xie D, et al., 2001), pancreatic cancers (Wenger C, et al., 1999), melanomas (Kubo M, 
et al., 1998), chondrosarcomas (Shakunaga T, et al., 2000), and squamous cell carcinomas 
(Shimo T, et al., 2008). Although CCN2 shows multiple roles in various cancer types, in 
breast tumor cells CCN2 over-expression has been linked to an increase in tumor size, 
lymph node metastasis (Chen PS, et al., 2007; Xie D, et al., 2001), and drug resistance 
through up-regulation of the survival pathway (Wang MY, et al., 2009). CCN2 is also 
regarded as a central mediator of tumor angiogenic factor in certain malignancies (Kondo S, 
et al., 2002; Shimo T, et al., 2001a; Shimo T, et al., 2001b). It should be noted that CCN2 is one 
of the contributors to bone metastasis, as it converts low-metastatic breast cancer cells to 
high-metastatic ones in collaboration with other factors (Kang Y, et al., 2003; Minn AJ, et al., 
2005). Neutralizing antibodies against CCN2 significantly inhibit local tumor growth, 
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angiogenesis, and osteolysis caused by metastatic human breast cancer cells (Shimo T, et al., 
2006). CCN2 and PTHrP are strongly expressed in cancer cells that have invaded the bone 
matrix, and CCN2 expression is regulated by PTHrP through PKA, PKC, and ERK1/2 
MAPK pathways (Shimo T, et al., 2006). Furthermore, the CCN2 gene is significantly over-
expressed in overt metastatic tumor cells as compared with its expression in disseminated 
tumor cells in the bone marrow of breast cancer patients by CT-guided bone metastasis 
biopsy and bone marrow biopsy (Cawthorn, et al., 2009). Fig. 2A illustrates a representative 
radiographic pattern of invasive bone destruction observed in a patient with oral squamous 
cell carcinoma in the mandibular region. In such cases, as shown in Fig. 2B, tumor cells fill 
the bone marrow space and destroy both the trabecular and cortical bone of the mandible. 
 
 
 
 
Fig. 2. Radiographic and immunohistochemical analysis of oral squamous cell carcinoma of 
the mandibular region. (A) Representative radiograph of an invasive oral squamous cell 
carcinoma in the mandibular region (arrowheads). (B) HE-stained sections of the resected 
mandible. Tumor tissue (Tm) has invaded into the marrow cavity and replaced the normal 
cellular elements. Significant loss of trabecular and cortical bone (Bn) has occurred. (C and 
D) Immunohistochemical staining of CCN2 in a section of invasive tumor (C) and of 
osteoclasts (D, arrowheads) of the resected mandible. Scale bar = 100 m. Bn: Bone, Tm: 
Tumor. The data were modified from Shimo et al. (Shimo, et al., 2008) (B and D). 
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CCN2 is abundantly produced by the tumor cells that have invaded the bone matrix (Fig. 
2C); and, interestingly, CCN2 is also present in the osteoclasts at the destroyed bone/tumor 
cell interface (Fig. 2D, arrowheads). Of note, up-regulation of CCN2 in oral squamous cell 
carcinoma of the mandible is associated with increased bone destruction (Shimo T, et al., 
2008). These data suggest that CCN2 can be considered both a diagnostic marker and target 
for treatment of oral osteolytic mandibular squamous cell carcinoma. 
3. Relation between CCN2 and tumor associated factors and signaling  
3.1 Insulin-like growth factor (IGF) and CCN2 
The insulin-like growth factor (IGF) is the most abundant factor stored in the bone matrix 
(Hauschka, et al., 1986). The IGF system comprises hormone-like growth factors (IGF-I and 
II), cell-surface receptors (IGF-IR, IGF-IIR and insulin receptor), circulating binding proteins 
(IGFBPs), and IGFBP proteases. Activation of IGF-I/IGFR signaling plays an important role 
in cancer cells, leading to an increase in cell proliferation, invasion/migration, to a decrease 
in apoptosis, and to resistance to antineoplastic agents, suggesting that IGF/IGFR plays an 
important role in mammary tumorigenesis (Brady, et al., 2007; Kimura, et al., 2010; Saxena, 
et al., 2008). A larger family of secreted cysteine-rich proteins, made so by inclusion of the 
Twisted gastrulation (TSG), IGFBP, and CCN families, is termed TIC (Flint, et al., 2008; Pell, 
et al., 2005). Interestingly, members of the CCN protein family bind IGF with low affinity 
(Hwa, et al., 1999). However, there are only a few published reports on the association 
between IGF system and CCN proteins. 
3.2 Parathyroid hormone-related protein (PTHrP) and CCN2 
Parathyroid hormone-related protein (PTHrP) has important developmental roles in the 
embryonic skeleton and other tissues. Detection or increased plasma concentrations of 
PTHrP have been found in 80% of hypercalcemia patients with solid tumor (Burtis WJ, et 
al., 1990). When it is produced in excess by cancer cells, it can cause hypercalcemia; and 
its local production by breast cancer cells has been implicated in the pathogenesis of bone 
metastasis in that disease. Localized production of PTHrP by cancer cells in such lesions 
was shown to promote the survival and proliferation of cancer cells and osteolysis in a 
mouse model (Guise TA, et al., 1996). PTHrP induces both the production of RANKL and 
down-regulation of OPG production by osteoblasts, thereby stimulating 
osteoclastogenesis (Horwood NJ, et al., 1998; Lee SK & Lorenzo JA, 1999). Oral squamous 
cell carcinoma cells provide a suitable microenvironment for osteoclast formation by 
producing PTHrP (Kayamori, et al., 2010). Knock-down of PTHrP in oral squamous cell 
carcinoma cell caused decreased osteoclast formation in vitro, and suppressed tumor bone 
invasion in vivo (Y. Takayama, et al., 2010). Sections of resected mandibles from patients 
with invasive oral squamous cell carcinoma showed strong expression of PTHrP in tumor 
cells and great number of osteoclasts at bone invasion sites (Y. Takayama, et al., 2010). 
Type I PTH/PTHrP receptor (PTH1R) expression is specifically observed in cancer cells 
producing PTHrP and CCN2 that have invaded the bone marrow, and PTHrP strongly 
up-regulates CCN2 in MDA-MB-231 cells in vitro (Shimo T, et al., 2006). CCN2 is also 
critically involved in osteolytic metastasis and is induced by PKA- and PKC-dependent 
activation of ERK 1/2 signaling by PTHrP (Shimo T, et al., 2006).  
www.intechopen.com
 Squamous Cell Carcinoma 
 
180 
3.3 Transforming growth factor- (TGF-) and CCN2 
TGF- is by far the second abundant cytokine in bone, and must be considered as a central 
player in bone turnover (Bonewald LF & Mundy GR, 1990) and potentially able to couple 
bone resorption with bone formation (Karsdal MA, et al., 2001; Takeshita S, et al., 2000). 
Restricted to the bone environment, target cells of TGF- include cancer cells as well as 
osteoblasts, osteoclasts, their precursors in the bone marrow, and stromal cells (Bonewald 
LF & Mundy GR, 1990; Karsdal MA, et al., 2001). TGF- is a pleiotropic cytokine that plays a 
central role in maintaining epithelial homeostasis. In early carcinogenesis, TGF- acts as a 
tumor suppressor by inhibiting cell proliferation (Massague J, et al., 2000; Sun L, 2004). 
However, several studies showed that primary tumor cells in the late stage can reprogram 
their response to TGF- by dysregulation or mutational inactivation of various components 
of the TGF- signaling pathway and through cross-interaction with other oncogenic 
pathways (Nagaraj & Datta, 2010). TGF- transduces its signal through 2 highly conserved 
single transmembrane serine/threonine kinase receptors, termed type I (T┚RI) and type II 
(T┚RII). T┚RII activates T┚RI upon formation of a ligand–receptor complex by 
hyperphosphorylating serine/threonine residues in the GS region of T┚RI. Activated T┚RI 
in turn phosphorylates Smad2 and Smad3, which interact with Smad4. Their complex is 
translocated to the nucleus, where it regulates the transcription of target genes. This 
signalling cascade initiates broad cellular and noncellular processes including proliferation 
and differentiation, migration and motility, and deposition of extracellular matrix, as well as 
induces the production of cytokines contributing to tumorigenesis, metastasis, and 
angiogenesis (Ge, et al., 2006; Petersen, et al., 2010). Due to its central role in TGF-┚ 
signalling, T┚RI is emerging as a novel target for the blockade of the tumor-promoting and 
metastasis activities of the TGF-┚ pathway (Shinto, et al., 2010). Consequently, the TGF- 
signal becomes a bone metastasis-promoting one (Kang Y, et al., 2005; Kominsky SL, et al., 
2007; Yin JJ, et al., 1999). T┚RI-positive signals are closely associated with destructive 
invasion of the mandible by oral squamous cell carcinoma cells, and a T┚RI-inhibitor greatly 
reduces oral squamous cell carcinoma cell-induced bone destruction and osteoclast 
formation both in vivo and in vitro (Goda, et al., 2010). 
TGF- is one of the most potent inducers of CCN2, promoting CCN2 expression in bone 
metastatic cancer cells (Kang Y, et al., 2003); and the induction occurs through a complex 
network of transcriptional interactions requiring Smads, protein kinase C, and 
ras/MEK/ERK, as well as an Ets-1/transcription enhancer factor-binding element in the 
CCN2 promoter (Chen Y, et al., 2002; Leask A, et al., 2002; Van Beek JP, et al., 2006). TGF-┚ 
released from the bone causes a further increase in the expression of the TGF-┚-responsive 
osteoclast-inducing genes, CCN2, RANKL, and TNF-┙ in oral squamous cell carcinoma cells, 
thus establishing a composite positive-feedback cycle of metastasis (Kang Y, et al., 2003; 
Shimo T, et al., 2006). 
3.4 RANKL and CCN2 
The RANK and its ligand RANKL signaling pathway play pivotal role in osteoclast-
mediated bone resorption in both normal bone remodeling and in pathological conditions, 
including bone metastasis (Boyle WJ, et al., 2003; Lacey DL, et al., 1998; Simonet WS, et al., 
1997). RANK is a transmembrane signaling receptor of the tumor necrosis factor (TNF) 
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receptor superfamily that is expressed on the surface of osteoclast precursors (Hsu H, et al., 
1999; Nakagawa N, et al., 1998). Its cognate ligand, RANKL, is expressed almost exclusively 
within the bone marrow stromal cell compartment and is up-regulated by most hormones 
and factors that stimulate bone resorption (Boyle WJ, et al., 2003; Roodman GD & Dougall 
WC, 2008). The interaction between RANK and RANKL is necessary for osteoclast 
formation, function, and survival (Kong YY, et al., 1999; Lacey DL, et al., 1998). RANKL (50 
ng/ml) stimulates osteoclastogenesis in mouse total bone marrow cells in the presence of 
100 ng/ml CCN2 (Shimo T, et al., 2008). Stromal/osteoblastic cells are essential for in vitro 
osteoclastogenesis through cell-to-cell interactions (Kondo Y, et al., 2001). The expression of 
CCN2 is up-regulated in the cells of mouse macrophage cell line RAW264.7 after treatment 
with RANKL, and CCN2 synergistically promotes RANKL-induced osteoclast 
differentiation by interacting with dendritic cell-specific transmembrane protein (DC-
STAMP) on the surface of osteoclast-like cells (Nishida, et al., 2011). Therefore, it has been 
hypothesized that CCN2 may facilitate cell-to-cell signaling by interacting with multiple 
molecules on the surface of these cells through integrin (Gao R & Brigstock DR, 2004; 
Hoshijima, et al., 2006), proteoglycans (Nishida, et al., 2003), and growth factors (Inoki I, et 
al., 2002).  
3.5 Endothelin-1 (ET-1) and CCN2 
Endothelin-1 (ET-1) is also a key mediator of osteoblastic bone metastasis, which is 
characteristic of breast and prostate cancers (Nelson JB, et al., 1995; Yin JJ, et al., 2003). 
Functional inhibition of ET-1 activity by blocking its receptor, ETA, significantly decreases 
bone metastasis in an experimental bone metastasis model involving the osteoblastic 
breast cancer cell line ZR-75-1 (Guise, et al., 2003; Yin JJ, et al., 2003).  
CCN2 is one of the secreted factors downstream of ET-1, as determined from microarray 
analysis of osteoblasts (Clines GA, et al., 2007). ET-1 activates the CCN2 promoter and 
induces CCN2 expression in cardiomyocyte cells (Recchia AG, et al., 2009). Furthermore, 
ET-1 induces CCN2 in an additive fashion with TGF-through an element distinct from the 
TGF- response element (Horstmeyer A, et al., 2005; Shi-Wen X, et al., 2008; Xu SW, et al., 
2004). 
3.6 Integrins and CCN2  
Integrin have been shown to be critical in controlling how tumor cells interact with their 
microenvironment. The integrin ┙v┚3 is a receptor for osteopontin, fibronectin, and 
vitronectin, which are extracellular matrix proteins important in the bone matrix 
(Schneider, et al., 2011); and ┙v┚3 has been identified as one of the CCN2 receptors (C. C. 
Chen, et al., 2001). Bone metastatic cancer cells have a higher expression of ┙v┚3 than their 
primary tumor (Liapis, et al., 1996), promoting adherence to the bone matrix (S. 
Takayama, et al., 2005). The over-expression of ┙v┚3 in the tumor cells not only leads to 
increased tumor cell adhesion, migration, and invasion to bone, but also increases 
osteoclast recruitment at the tumor and bone interface (Pecheur, et al., 2002; Sloan, et al., 
2006). Whereas, ┙5┚1, another signaling receptor mediating CCN2 action, plays a 
necessary role in the binding of prostate cancer tumor cells to the bone stroma (Van der 
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Velde-Zimmermann, et al., 1997), and in skeletal metastasis of breast cancer cells (Korah, 
et al., 2004). 
Bone-invading destructive tumor cells enhance osteoclast function and recruitment. ┙v┚3 is 
the predominant integrin found on osteoclasts, and is responsible for mediating osteoclast-
bone recognition (Crippes, et al., 1996; Liapis, et al., 1996; Ross, et al., 1993; Zambonin 
Zallone, et al., 1989) and subsequent attachment to the bone matrix (Chellaiah, 2006; Ross, et 
al., 1993). This signaling creates the characteristic resorptive ruffled membrane, as well as 
regulates OC spreading and the overall organization of the cytoskeleton (Faccio, et al., 2003; 
McHugh, et al., 2000).  
3.7 Wnt signaling and CCN2 
The Wnt signaling pathways are initiated by a combination of ligands and receptors formed 
from among 19 secreted Wnt ligands, 10 Frizzled receptors, with the involvement of the co-
receptor LRP5/6, which is lipoprotein receptor-related protein 5/6. These ligand-receptor 
interactions then lead to the activation of multiple intermediate Wnt effectors including ┚-
catenin, c-Jun-NH2-kinase, and calcium-channel regulators. The accumulation of ┚-catenin 
in the cytoplasm and its translocation to the nucleus represent the hallmark of the activated 
canonical Wnt pathway. In the nucleus, ┚-catenin forms a complex with lymphocyte 
enhancer factor/T-cell factor family of transcription factors to activate many oncogenes, 
such as c-Myc, cyclin D1, metalloproteinases, c-Met, etc (Fuerer, et al., 2008; Rubin, et al., 
2010). 
The Wnt/┚-catenin signaling pathway is an important target for eliminating cancer stem cell 
in head and neck squamous cell carcinomas (Song, et al., 2010). The importance of paracrine 
Wnt signaling in bone metastasis was first revealed in multiple myeloma (Tian, et al., 2003), 
a plasma cell leukemia that causes severe osteolytic bone disease. The results revealed that 
one of the tumor-secreted factors responsible for the enhanced osteolysis is the Wnt-
inhibitor DKK-1 (Tian, et al., 2003). In prostate cancer cells, high DKK-1 expression is 
correlated with osteolytic disease, consistent with the findings in multiple myeloma; 
whereas low DKK-1 expression is associated with osteosclerotic bone metastases 
(Schwaninger, et al., 2007). Functional inhibition of Wnt singling by DKK-1 over-expression 
in prostate cancer cells favors the formation of osteolytic bone metastases (Hall, et al., 2005).  
Si et al. (Si, et al., 2006) observed a significant up-regulation of CCN2 gene expression in 
mesenchymal stem cells that had been stimulated by Wnt3A. Osteoblasts and stromal cells 
of transgenic mice that over-express CCN2 display reduced Wnt-┚-catenin signaling 
(Smerdel-Ramoya, et al., 2008). Over-expression of CCN2 in esophageal squamous 
carcinoma cells results in the accumulation and nuclear translocation of ┚-catenin leading to 
activation of TCF-LEF signaling and up-regulation of c-myc and cyclin D1 (Deng, et al., 
2007). 
4. Role of CCN2 in tumor/bone microenvironment  
In the bone marrow microenvironment affected by a tumor, substantial bone marrow 
angiogenesis is present compared with that in healthy persons (Chavez-Macgregor, et al., 
2005). CCN2, the best-characterized factor in its family is known to promote the proliferation 
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Fig. 3. Role of CCN2 in tumor-induced bone destruction. The cross-talk between tumor cells 
and osteoclasts is not direct, but involves molecular and cellular intermediates; e.g., tumor 
cells secrete parathyroid-hormone-related peptide (PTHrP), which is the primary stimulator 
of osteoblast production of RANKL (Roodman GD, 2004). PTHrP induces CCN2 in tumor 
cells (Shimo T, et al., 2008); on the other hand, PTHrP both up-regulates the production of 
RANKL and down-regulates OPG production by osteoblasts, thereby stimulating 
osteoclastogenesis (Horwood NJ, et al., 1998). Other factors produced and secreted by tumor 
cells (TNF-, TGF-, macrophage colony-stimulating factor (M-CSF), IL-6, and 
prostaglandin E2) also increase the expression of RANKL. The increased expression of 
RANKL in the tumor environment leads to increased formation, activation, and survival of 
osteoclasts, which cells cooperate with these tumor-induced growth factors (CCN2, TNF-, 
TGF-, and M-CSF), resulting in osteolytic lesions. Osteolysis then leads to the release of 
growth factors derived from bone, including transforming growth factor- (TGF-), insulin-
like growth factors (IGFs), fibroblast growth factors (FGFs), platelet-derived growth factor 
(PDGF), and bone morphogenetic proteins (BMPs). These factors increase the production of 
PTHrP and CCN2 or promote tumor growth directly and cause neovascularization. Bone 
destruction increases local extracellular calcium (Ca2+) concentrations, which have also been 
shown to promote tumor growth and the production of PTHrP (Roodman GD, 2004). Thus, 
tumor cell proliferation and production of tumor-associated factors through the signaling of 
positive-feedback pathways is promoted, thus giving rise to a “vicious cycle.” The Scheme 
was modified from (Shimo T, et al., 2011). 
  
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and differentiation of not only vascular endothelial cells but also fibroblasts and 
osteoblasts (C. C. Chen, et al., 2001; Nishida T, et al., 2000; Shimo T, et al., 1998; Shimo T, 
et al., 1999). CCN2 protein is able to interact with multiple molecules in the bone 
microenvironment, which interaction results in the modulation of the extracellular 
molecular network therein. The angiogenic effect of CCN2 is the result of the interaction 
of it with adhesion molecules (Gao R & Brigstock DR, 2004), cell-surface signal 
transducing receptors (Wahab, et al., 2005), proteoglycans (Nishida, et al., 2003), and 
growth factors (Inoki I, et al., 2002).  
Bone-derived growth factors, such as TGF-, FGFs, PDGFs, BMPs, and IGF-1, are activated 
and released into the bone microenvironment. Elevated TGF- does not appear to affect 
tumor growth, but rather leads to the production of PTHrP (Guise TA, 2000) and CCN2 
(Kang Y, et al., 2003; Shimo T, et al., 2006) in cancer cells, thus establishing a continuously 
destructive cycle termed the “vicious cycle” through up-regulation of RANKL and 
accelerated bone resorption. Of note, CCN2 is known to interact with these growth factors 
(Abreu JG, et al., 2002; Inoki I, et al., 2002) or regulate the gene expression of some of them 
(Shimo T, et al., 2001b). As a result, CCN2 may be anticipated to modulate the effects of 
these growth factors on the osteoblast-induced RANKL and OPG expression, osteoclast 
formation or osteoclast activation in regions affected by bone metastasis (Fig. 3). The other 
critical function of CCN2 is exerted by its interaction with extracellular matrix molecules 
and cell-adhesion molecules. By interacting with integrins, functions and other proteins and 
proteoglycans, CCN2 may promote adhesion and migration of osteoclast precursor cells and 
stimulate osteoclast formation and activation (Shimo T, et al., 2008). CCN2 not only 
promotes the expression of DC-STAMP, which plays an important role in cell-cell fusion, 
but also interacts with this molecule to promote osteoclast differentiation (Nishida, et al., 
2011). CCN2 may thus be an integrator/modulator of extracellular information and appears 
to allow the establishment and progression of tumor angiogenesis and bone destruction 
within the skeleton (Kubota S & Takigawa M, 2007a; Sasaki A, et al., 1998; Sasaki A, et al., 
2003). 
5. Conclusions 
The initiation of osteoclastogenesis and angiogenesis is the most fundamental step leading 
to tumor-induced bone destruction. From a clinical point of view, osteoclast formation and 
angiogenesis would be the major targets of therapeutic drugs for tumor bone metastasis. 
The major modulator of these processes, referring to osteoclast formation and angiogenesis 
has been shown to be the CCN2 molecule, which is thus now regarded as a potential target 
of anti-osteoclastogenic and angiogenic therapy (Aikawa, et al., 2006; Shimo T, et al., 2006). 
These findings strongly suggest that CCN2 may be a suitable molecular target for therapy of 
advanced oral squamous cell carcinoma. 
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